COX-1/2-IN-9

• UNSPSC Description:

  COX-1/2-IN-9 (Compound 3n) is a potent and selective inhibitor of COX-1/2, with IC50 values of 0.031 µM and 0.01 µM, respectively. COX-1/2-IN-9 possesses both antibacterial and anti-inflammatory activities, effectively inhibiting MRSA 1478 (MIC=50 μg/mL) and multidrug-resistant S. lentus (MIC=50 μg/mL). COX-1/2-IN-9 holds significant potential to alleviate MRSA-induced pneumonia in immunocompromised states[1].

• Target Antigen:

  Bacterial; COX

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cox-1-2-in-9.html

• Smiles:

  IC1=CC2=C(N=C(SCC(NC3=CC=C([N+]([O-])=O)C=C3[N+]([O-])=O)=O)N(C4=CC=C(S(=O)(NCC(NC5=CC=C([N+]([O-])=O)C=C5[N+]([O-])=O)=O)=O)C=C4)C2=O)C=C1

• Molecular Weight:

  905.57

• References & Citations:

  [1]Soliman A M, et al. Novel quinazoline sulfonamide-based scaffolds modulate methicillin-resistant Staphylococcus aureus (MRSA) pneumonia in immunodeficient irradiated model: Regulatory role of TGF-β[J]. Bioorganic Chemistry, 2024: 107559.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported